Scholarlink

Purpose <p>To assess the effect of increased injection volume on intraocular pressure (IOP) following intravitreal injections of aflibercept 8 mg (70 µl) compared to conventional anti-vascular endothelial growth factor drugs.</p> Study design <p>Retrospective observational study</p> Methods <p>This retrospective observational study included eyes treated with 50 µl of either aflibercept 2 mg or faricimab 6 mg, followed by a switch to 70 µl of aflibercept 8 mg. IOP was measured before and 30 minutes after intravitreal injections. IOP changes in treated and fellow eyes were analyzed, with potential associations examined between IOP changes and clinical parameters.</p> Results <p>A total of 88 eyes from 85 patients were switched to aflibercept 8 mg during the study period. Due to incomplete data, 17 eyes from 15 patients were excluded, leaving 71 eyes from 70 patients for the analysis. IOP significantly increased from 13.2 ± 2.9 mmHg to 19.1± 5.4 mmHg (<i>P</i>&lt; 0.001) with 50 µl injections and from 13.3 ± 2.9 mmHg to 19.8 ± 4.8 mmHg (<i>P</i>&lt;0.001) with 70 µl injections. The IOP increases were 6.0 ± 5.0 mmHg with 50 µl injections and 6.5 ± 4.3 mmHg with 70 µl injections, with no statistically significant difference (<i>P</i> = 0.20). An IOP exceeding 26 mmHg was observed in 6 eyes treated with 50 µl injections and 10 eyes with 70 µl injections, with no significant difference in IOP distribution between the volumes (P = 0.20).</p> Conclusion <p>There was no additional increase in IOP 30 minutes after intravitreal injections when switching from 50 µl to 70 µl volumes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of intraocular pressure elevation following intravitreal injection of 70 µl aflibercept 8 mg

  • 期刊论文

  • 发表日期：

    2025年6月26日

查看全文
  • Xien Lu,
  • Keiko Kataoka,
  • Mariko Kumagai,
  • Yuta Nochi,
  • Akiko Yamamoto,
  • Rie Ko,
  • Annabelle A Okada

摘要

Purpose

To assess the effect of increased injection volume on intraocular pressure (IOP) following intravitreal injections of aflibercept 8 mg (70 µl) compared to conventional anti-vascular endothelial growth factor drugs.

Study design

Retrospective observational study

Methods

This retrospective observational study included eyes treated with 50 µl of either aflibercept 2 mg or faricimab 6 mg, followed by a switch to 70 µl of aflibercept 8 mg. IOP was measured before and 30 minutes after intravitreal injections. IOP changes in treated and fellow eyes were analyzed, with potential associations examined between IOP changes and clinical parameters.

Results

A total of 88 eyes from 85 patients were switched to aflibercept 8 mg during the study period. Due to incomplete data, 17 eyes from 15 patients were excluded, leaving 71 eyes from 70 patients for the analysis. IOP significantly increased from 13.2 ± 2.9 mmHg to 19.1± 5.4 mmHg (P< 0.001) with 50 µl injections and from 13.3 ± 2.9 mmHg to 19.8 ± 4.8 mmHg (P<0.001) with 70 µl injections. The IOP increases were 6.0 ± 5.0 mmHg with 50 µl injections and 6.5 ± 4.3 mmHg with 70 µl injections, with no statistically significant difference (P = 0.20). An IOP exceeding 26 mmHg was observed in 6 eyes treated with 50 µl injections and 10 eyes with 70 µl injections, with no significant difference in IOP distribution between the volumes (P = 0.20).

Conclusion

There was no additional increase in IOP 30 minutes after intravitreal injections when switching from 50 µl to 70 µl volumes.